William Montague - Endo International Director
Director
Mr. William P. Montague, is Independent Director of Endo International Public Limited Company. since 2009. Mr. Montague is Chairman of Endos Compensation Committee, a member of Endos Audit Committee and an alternate member of Endos Nominating Governance Committee. Mr. Montague served as Chief Executive Officer of Mark IV Industries, Inc., a leading global diversified manufacturer of highly engineered systems and components for transportation infrastructure, vehicles and equipment, from November 2004 until his retirement in July 2008 and as Director from March 1996. He joined Mark IV Industries in April 1972 as TreasurerController, serving as Vice President of Finance from May 1974 to February 1986, then Executive Vice President and Chief Financial Officer from February 1986 to March 1996 and then as President from March 1996 to November 2004. Mr. Montague is also a Director of Gibraltar Industries, Inc., a publicly traded manufacturer and distributor of products for the building and industrial markets since 1993, and has served as Chairman of Gibraltars Board of Directors since June 2015. From February 2013 until May 2014, Mr. Montague served as a Director of Allied Motion Technologies Inc., a publicly traded company focused exclusively on serving the motion control market. From February 2009 until February 2014, Mr. Montague was a Director of Endo Health Solutions Inc. since 2009.
| Age | 71 |
| Tenure | 15 years |
| Phone | 353 1 268 2000 |
| Web | https://www.endo.com |
Endo International Management Efficiency
The company has return on total asset (ROA) of 5.11 % which means that it generated a profit of $5.11 on every $100 spent on assets. This is normal as compared to the sector avarege. Endo International's management efficiency ratios could be used to measure how well Endo International manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 8.13 B in liabilities with Debt to Equity (D/E) ratio of 1.98, which is about average as compared to similar companies. Endo International PLC has a current ratio of 1.77, which is within standard range for the sector. Debt can assist Endo International until it has trouble settling it off, either with new capital or with free cash flow. So, Endo International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endo International PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endo to invest in growth at high rates of return. When we think about Endo International's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Douglas Ammerman | El Pollo Loco | 63 | |
| David Jones | Dave Busters Entertainment | 64 | |
| Carol Lynton | El Pollo Loco | 56 | |
| Alice Cheng | NetEase | 55 | |
| Matthew Peltz | The Wendys Co | 35 | |
| Kilandigalu Madati | Wingstop | 44 | |
| Hamish Dodds | Dave Busters Entertainment | 60 | |
| Joseph Tong | NetEase | 53 | |
| Kristin Dolan | The Wendys Co | 51 | |
| Michael Hislop | Wingstop | 63 | |
| Jennifer Storms | Dave Busters Entertainment | 45 | |
| Kevin Mailender | Dave Busters Entertainment | 36 | |
| William Floyd | El Pollo Loco | 73 | |
| Wesley Barton | El Pollo Loco | 36 | |
| Sebastian Jaume | Meli Hotels International | N/A | |
| Wesley McDonald | Wingstop | 54 | |
| Alfredo Bodmer | Meli Hotels International | N/A | |
| Juan Cerda | Meli Hotels International | N/A | |
| Kelsey Freed | The Wendys Co | N/A | |
| Kevin Sheehan | Dave Busters Entertainment | 64 | |
| Carina Lazaro | Meli Hotels International | N/A | |
Management Performance
| Return On Equity | 0.007 | |||
| Return On Asset | 5.11 |
Endo International PLC Leadership Team
Elected by the shareholders, the Endo International's board of directors comprises two types of representatives: Endo International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endo. The board's role is to monitor Endo International's management team and ensure that shareholders' interests are well served. Endo International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endo International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
| William Spengler, Director | ||
| Arthur Higgins, Independent Director | ||
| Brian Lortie, President U.S. Branded Pharmaceuticals | ||
| Donald DeGolyer, Special Advisor to the CEO | ||
| William Montague, Director | ||
| Michael Hyatt, Director | ||
| Douglas Ingram, Director | ||
| Antonio Pera, President - Par Pharmaceutical | ||
| Domenic Ciarico, Executive Vice President Chief Commercial Officer - Sterile and Generics | ||
| Roger Kimmel, Chairman of the Board | ||
| Susan Hall, Chief Scientific Officer, Global Head of RandD and Quality and Executive VP | ||
| Sharad Mansukani, Director | ||
| Suketu Upadhyay, CFO and Executive VP | ||
| Nancy Hutson, Independent Director | ||
| Todd Sisitsky, Director | ||
| Patrick Barry, Executive Vice President and Chief Commercial Officer | ||
| Shane Cooke, Independent Director | ||
| Craig Paterson, Chief Medical Officer | ||
| Daniel Rudio, Senior Vice President Chief Accounting Officer, Controller | ||
| Camille Farhat, President of American Medical Systems, Inc | ||
| Paul Campanelli, President CEO, Director | ||
| Jill Smith, Director | ||
| Rajiv Silva, CEO and President and Director | ||
| Nina Goworek, Senior Director, Investor Relations | ||
| Blaise Coleman, Senior Vice President of Global Finance Operations and Interim CFO | ||
| Terrance Coughlin, COO, Executive Vice President | ||
| Matthew Maletta, Executive Vice President Chief Legal Officer |
Endo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endo International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.007 | |||
| Return On Asset | 5.11 | |||
| Profit Margin | (24.82) % | |||
| Operating Margin | 24.70 % | |||
| Current Valuation | 6.84 B | |||
| Shares Outstanding | 233.67 M | |||
| Shares Owned By Insiders | 0.79 % | |||
| Shares Owned By Institutions | 83.64 % | |||
| Number Of Shares Shorted | 41.45 M | |||
| Price To Earning | 0.37 X |
Pair Trading with Endo International
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endo International position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endo International will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to US Bancorp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace US Bancorp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back US Bancorp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling US Bancorp to buy it.
The correlation of US Bancorp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as US Bancorp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if US Bancorp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for US Bancorp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Endo International PLC information on this page should be used as a complementary analysis to other Endo International's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Endo Stock
If you are still planning to invest in Endo International PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Endo International's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |